Isogenica was a biotechnology company that specialized in protein engineering and synthetic biology platforms for pharmaceutical and biotechnology applications. The company developed proprietary technologies for protein discovery, optimization, and production, serving both internal drug development programs and external pharmaceutical partners. Isogenica's platforms enabled the rapid discovery and development of novel therapeutic proteins, including antibodies and other biologics, with applications across various disease areas.
Isogenica has received investment from 1 venture capital firm.
Biotechnology company developing protein engineering and synthetic biology platforms for drug discovery and development.
Isogenica has received investment from Cambridge Innovation Capital. These venture capital firms and investors provide both capital and strategic support.
Isogenica was founded in 2000 and is headquartered in Cambridge, UK.
Isogenica operates in the Biotech sector. Biotechnology company developing protein engineering and synthetic biology platforms for drug discovery and development.
